Literature DB >> 27221700

End-stage liver disease patients with MELD >40 have higher waitlist mortality compared to Status 1A patients.

Joseph Ahn1, Taft Bhuket2, Sasan Mosadeghi2, Catherine Frenette3, Benny Liu2, Robert J Wong4.   

Abstract

BACKGROUND AND AIMS: Status 1A patients are prioritized over end-stage liver disease (ESLD) for liver transplantation (LT). ESLD patients with high MELD may have higher waitlist mortality than Status 1A patients, and may require LT more urgently.
METHODS: Using United Network for Organ Sharing registry data, we retrospectively evaluated LT waitlist mortality and probability of LT between adults in the United States with Status 1A or ESLD with MELD >30 listed for LT from 2003-2013. Overall waitlist mortality and probability of LT were evaluated with Kaplan-Meier and multivariate logistic regression models.
RESULTS: From 2003-2013, 15,049 ESLD patients with MELD >30 and 3049 Status 1A patients were listed for LT. While overall 14-day waitlist survival decreased with increasing MELD score among ESLD patients (54.0 % for MELD 31-35; 37.1 % for MELD 36-40; 27.5 % for MELD >40), overall survival at 14 days was significantly lower among Status 1A (14.4 %). Compared to Status 1A, ESLD patients with MELD >40 had significantly higher 14-day waitlist mortality (OR 1.92; 95 % CI 1.56-2.36; p < 0.001), whereas ESLD patients with MELD 36-40 had a non-significant trend towards higher waitlist mortality (OR 1.16; 95 % CI 0.93-1.45; p = 0.181). No difference in probability of LT within 14 days was observed between ESLD with MELD >40 and Status 1A (p = 0.89). ESLD patients with MELD >40 had higher post-LT survival compared to Status 1A on multivariate regression modeling (HR 0.80; 95 % CI 0.66-0.96; p < 0.02).
CONCLUSION: Among adults in the United States awaiting LT, ESLD patients with MELD >40 have significantly higher waitlist mortality, but similar probability of receiving LT compared to Status 1A patients.

Entities:  

Keywords:  Liver failure; Liver transplantation; Status 1A; UNOS/OPTN; Waitlist survival

Mesh:

Year:  2016        PMID: 27221700     DOI: 10.1007/s12072-016-9735-4

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  21 in total

1.  Organ Procurement and Transplantation Network. Health Resources and Services Administration, HHS. Final rule.

Authors: 
Journal:  Fed Regist       Date:  1999-10-20

2.  AASLD practice guidelines: Evaluation of the patient for liver transplantation.

Authors:  Karen F Murray; Robert L Carithers
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

3.  OPTN/SRTR 2013 Annual Data Report: liver.

Authors:  W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2015-01       Impact factor: 8.086

4.  Early post-transplant survival: Interaction of MELD score and hospitalization status.

Authors:  Therese Bittermann; George Makar; David S Goldberg
Journal:  J Hepatol       Date:  2015-04-07       Impact factor: 25.083

5.  Early changes in liver distribution following implementation of Share 35.

Authors:  A B Massie; E K H Chow; C E Wickliffe; X Luo; S E Gentry; D C Mulligan; D L Segev
Journal:  Am J Transplant       Date:  2015-03       Impact factor: 8.086

6.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

7.  End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates.

Authors:  Pratima Sharma; Douglas E Schaubel; Qi Gong; Mary Guidinger; Robert M Merion
Journal:  Hepatology       Date:  2011-11-15       Impact factor: 17.425

8.  The survival benefit of liver transplantation.

Authors:  Robert M Merion; Douglas E Schaubel; Dawn M Dykstra; Richard B Freeman; Friedrich K Port; Robert A Wolfe
Journal:  Am J Transplant       Date:  2005-02       Impact factor: 8.086

9.  MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients.

Authors:  Walter K Kremers; Marrije van IJperen; W Ray Kim; Richard B Freeman; Ann M Harper; Patrick S Kamath; Russell H Wiesner
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

10.  Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011.

Authors:  William M Lee; R Todd Stravitz; Anne M Larson
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

View more
  3 in total

1.  Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a Patients.

Authors:  Vinay Sundaram; Parth Shah; Robert J Wong; Constantine J Karvellas; Brett E Fortune; Nadim Mahmud; Alexander Kuo; Rajiv Jalan
Journal:  Hepatology       Date:  2019-05-17       Impact factor: 17.425

2.  Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no?"

Authors:  Olivia S Kates; Cynthia E Fisher; Robert M Rakita; Jorge D Reyes; Ajit P Limaye
Journal:  Am J Transplant       Date:  2020-06-11       Impact factor: 9.369

Review 3.  Transplantation in the era of the Covid-19 pandemic: How should transplant patients and programs be handled?

Authors:  Mohamed M NasrAllah; Noha A Osman; Mahmoud Elalfy; Paolo Malvezzi; Lionel Rostaing
Journal:  Rev Med Virol       Date:  2020-09-20       Impact factor: 11.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.